{"id":"https://openalex.org/W2108059892","doi":"https://doi.org/10.1517/14740338.5.6.835","title":"Clinical safety of the selective PKC-\u03b2 inhibitor, ruboxistaurin","display_name":"Clinical safety of the selective PKC-\u03b2 inhibitor, ruboxistaurin","publication_year":2006,"publication_date":"2006-10-18","ids":{"openalex":"https://openalex.org/W2108059892","doi":"https://doi.org/10.1517/14740338.5.6.835","mag":"2108059892","pmid":"https://pubmed.ncbi.nlm.nih.gov/17044810"},"language":"en","primary_location":{"id":"doi:10.1517/14740338.5.6.835","doi":"https://doi.org/10.1517/14740338.5.6.835","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14740338.5.6.835","pdf_url":null,"source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050076657","display_name":"Janet B. McGill","orcid":"https://orcid.org/0000-0002-6228-6521","observed_orcids":["https://orcid.org/0000-0002-6228-6521"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janet B McGill","raw_affiliation_strings":["Washington University School of Medicine, 660 S. Euclid, Campus Box 8127, St. Louis, MO 63110, USA. jmcgill@im.wustl.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine, 660 S. Euclid, Campus Box 8127, St. Louis, MO 63110, USA. jmcgill@im.wustl.edu","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009528569","display_name":"George Liang King","orcid":"https://orcid.org/0000-0002-0335-5881","observed_orcids":["https://orcid.org/0000-0002-0335-5881"]},"institutions":[{"id":"https://openalex.org/I1293231726","display_name":"Joslin Diabetes Center","ror":"https://ror.org/0280a3n32","country_code":"US","type":"facility","lineage":["https://openalex.org/I1293231726"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George L King","raw_affiliation_strings":["Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I1293231726","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049673791","display_name":"Paul H. Berg","orcid":"https://orcid.org/0000-0001-8418-6815","observed_orcids":["https://orcid.org/0000-0001-8418-6815"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul H Berg","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA","Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Karen L Price","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen L Price","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA","Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006598998","display_name":"Keri A. Kles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keri A Kles","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA","Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061691275","display_name":"Edward J. Bastyr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I4394709130","display_name":"Indiana University School of Medicine","ror":"https://ror.org/02ets8c94","country_code":"US","type":"education","lineage":["https://openalex.org/I4394709130","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward J Bastyr","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; Indiana University School of Medicine, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; Indiana University School of Medicine, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I4394709130"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021501902","display_name":"David L. Hyslop","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David L Hyslop","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA","Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.243,"has_fulltext":false,"cited_by_count":48,"citation_normalized_percentile":{"value":0.69230769,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"5","issue":"6","first_page":"835","last_page":"845"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.3991999924182892,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.3991999924182892,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.22660000622272491,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.02539999969303608,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ruboxistaurin","display_name":"ruboxistaurin","score":0.996999979019165},{"id":"https://openalex.org/keywords/protein-kinase-c-beta-inhibitor","display_name":"protein kinase C beta inhibitor","score":0.871999979019165},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7720000147819519},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.7799999713897705},{"id":"https://openalex.org/keywords/diabetes-mellitus","display_name":"diabetes mellitus","score":0.6570000052452087},{"id":"https://openalex.org/keywords/long-term-tolerability","display_name":"long-term tolerability","score":0.777999997138977},{"id":"https://openalex.org/keywords/serious-adverse-events","display_name":"serious adverse events","score":0.8939999938011169},{"id":"https://openalex.org/keywords/dyspepsia","display_name":"dyspepsia","score":0.8109999895095825},{"id":"https://openalex.org/keywords/creatine-kinase-elevation","display_name":"creatine kinase elevation","score":0.8989999890327454}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9362368583679199},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.8227560520172119},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7455534338951111},{"id":"https://openalex.org/C2780194963","wikidata":"https://www.wikidata.org/wiki/Q903441","display_name":"Mesylate","level":2,"score":0.7027231454849243},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5172482132911682},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4587128758430481},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4286785125732422},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.42711830139160156},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4183975160121918},{"id":"https://openalex.org/C36880943","wikidata":"https://www.wikidata.org/wiki/Q409458","display_name":"Creatine kinase","level":2,"score":0.41231778264045715},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34716594219207764},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.10528454184532166},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0698789656162262},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D008301","descriptor_name":"Maleimides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011493","descriptor_name":"Protein Kinase C","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D011493","descriptor_name":"Protein Kinase C","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D064546","descriptor_name":"Protein Kinase C beta","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14740338.5.6.835","doi":"https://doi.org/10.1517/14740338.5.6.835","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14740338.5.6.835","pdf_url":null,"source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},{"id":"pmid:17044810","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17044810","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on drug safety","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W30216345","https://openalex.org/W1496977463","https://openalex.org/W1511426001","https://openalex.org/W1578810619","https://openalex.org/W1591039074","https://openalex.org/W1932654578","https://openalex.org/W1966419887","https://openalex.org/W1977879939","https://openalex.org/W1988143227","https://openalex.org/W1988293663","https://openalex.org/W1992451339","https://openalex.org/W1997926000","https://openalex.org/W2001129294","https://openalex.org/W2025589178","https://openalex.org/W2049945223","https://openalex.org/W2055168506","https://openalex.org/W2057216389","https://openalex.org/W2060390249","https://openalex.org/W2070593849","https://openalex.org/W2084691395","https://openalex.org/W2084823433","https://openalex.org/W2102719227","https://openalex.org/W2104969843","https://openalex.org/W2120480620","https://openalex.org/W2122107343","https://openalex.org/W2124521298","https://openalex.org/W2128338810","https://openalex.org/W2133191530","https://openalex.org/W2159337738","https://openalex.org/W2167764610","https://openalex.org/W2337454357","https://openalex.org/W2591764924","https://openalex.org/W2769264260"],"related_works":["https://openalex.org/W2401009382","https://openalex.org/W4254504416","https://openalex.org/W2142484191","https://openalex.org/W2317852218","https://openalex.org/W2169423814","https://openalex.org/W2218231789","https://openalex.org/W7167288403","https://openalex.org/W2885646463","https://openalex.org/W2151628775","https://openalex.org/W2417629502"],"abstract_inverted_index":{"The":[0,49],"aim":[1],"of":[2,11,51,90],"this":[3,86],"manuscript":[4],"is":[5],"to":[6,28,95,139],"report":[7],"the":[8,64,69,91,99,117],"safety":[9],"profile":[10,137],"patients":[12,33,52,119],"treated":[13],"with":[14,34],"ruboxistaurin":[15],"mesylate":[16],"(RBX;":[17],"LY333531),":[18],"a":[19],"selective":[20],"protein":[21],"kinase":[22],"C-beta":[23],"(PKC-beta)":[24],"inhibitor,":[25],"for":[26],"up":[27],"4":[29],"years.":[30],"Data":[31],"from":[32,44],"diabetes":[35],"(1396":[36],"RBX":[37,132],"32":[38],"mg/day;":[39],"1408":[40],"placebo)":[41,83],"were":[42,77,114,120],"combined":[43],"11":[45],"placebo-controlled,":[46],"double-masked":[47],"studies.":[48],"proportion":[50],"who":[53],"reported":[54,84,115],"one":[55],"or":[56,106],"more":[57],"serious":[58],"adverse":[59,102,135],"events":[60],"was":[61,93,142],"greater":[62],"in":[63,68,85,116],"placebo":[65],"group":[66,71],"than":[67],"RBX-treated":[70,118],"(23.2":[72],"versus":[73],"20.8%,":[74],"respectively).":[75],"There":[76],"51":[78],"deaths":[79,92],"(21":[80],"RBX;":[81],"30":[82],"patient":[87],"cohort;":[88],"none":[89],"attributed":[94],"study":[96],"drug":[97,103],"by":[98],"investigators.":[100],"Common":[101],"reactions":[104],"(>":[105],"=":[107],"1/100":[108],"-":[109],"<":[110],"1/10":[111],"patients)":[112],"that":[113],"dyspepsia":[121],"and":[122,141],"increased":[123],"blood":[124],"creatine":[125],"phosphokinase.":[126],"In":[127],"controlled,":[128],"randomised":[129],"clinical":[130],"trials,":[131],"had":[133],"an":[134],"event":[136],"comparable":[138],"placebo,":[140],"well":[143],"tolerated.":[144]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}